Jane Street’s TScan Therapeutics TCRX Stock Holding History

Jane Street’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$237K	Buy	241,493 +97,072	+67%	+$103K	﹤0.01%	9725
2026 Q1	$146K	Sell	144,421 -243,863	-63%	-$261K	﹤0.01%	10411
2025 Q4	$388K	Buy	388,284 +306,968	+378%	+$444K	﹤0.01%	8258
2025 Q3	$148K	Sell	81,316 -132,080	-62%	-$234K	﹤0.01%	9893
2025 Q2	$309K	Buy	+213,396	New	+$308K	﹤0.01%	7805
2024 Q4	–	Sell	-93,876	Closed	-$468K	–	10564
2024 Q3	$468K	Sell	93,876 -5,160	-5%	-$31.1K	﹤0.01%	7304
2024 Q2	$579K	Sell	99,036 -54,097	-35%	-$426K	﹤0.01%	6767
2024 Q1	$1.22M	Buy	153,133 +69,511	+83%	+$437K	﹤0.01%	5051
2023 Q4	$488K	Buy	+83,622	New	+$383K	﹤0.01%	6798
2022 Q3	–	Sell	-10,176	Closed	-$32K	–	10456
2022 Q2	$32K	Buy	+10,176	New	+$27.8K	﹤0.01%	9042
2022 Q1	–	Sell	-11,307	Closed	-$51K	–	11013
2021 Q4	$51K	Buy	+11,307	New	+$81.6K	﹤0.01%	9528

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Jane Street's TCRX Position: Q2 2026 in Review

Jane Street increased its TScan Therapeutics (TCRX) stake by 67% in Q2 2026, buying an estimated $103K and bringing the position to 241,493 shares worth $237K. The position accounts for ﹤0.01% of the portfolio, ranked #9725.

Jane Street first reported a position in TCRX in Q4 2021 and has held it in 11 quarters since. The position peaked at $1.22M in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

Jane Street held 241,493 shares of TScan Therapeutics worth $237K as of Q2 2026.
Jane Street bought 97,072 TScan Therapeutics shares in Q2 2026, an estimated $103K.
TScan Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #9725 holding.
Jane Street first reported a position in TScan Therapeutics in Q4 2021 and has held it in 11 quarters since.
Jane Street's TScan Therapeutics position peaked at $1.22M in Q1 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.